Overview on Anticancer Drug Design and Development

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Current anti-cancer therapies face significant challenges, driving the need for novel therapeutic agents.
• Advances in understanding cancer biology have led to new targets and strategies, including monoclonal antibodies, tyrosine kinase inhibitors, and epigenetic drugs entering clinical trials.

Purpose of the Study:

• To review the rationale behind developing inhibitors for major cancer targets (cell growth, proliferation, survival, angiogenesis) and emerging targets (proteasome, heat shock proteins, epigenetics).
• To discuss factors influencing drug resistance, such as metabolic changes, hypoxia, and cancer precursors.
• To explain the role of computational techniques in identifying cancer targets and designing selective inhibitors.

Main Methods:

• Highlighting recent target-based anti-cancer drug development approaches with examples of approved agents.
• Discussing factors contributing to drug resistance and their impact.
• Explaining the application of advanced computational techniques in target identification and inhibitor design.

Main Results:

• Recent techniques like network analysis and biomolecular simulations aid in clarifying targets, mechanisms of action, and reasons for drug inefficacy.
• The interplay between various anti-cancer mechanisms and molecular design strategies is explored.
• Computational methodologies are crucial for understanding drug efficacy and resistance.

Conclusions:

• This review summarizes key targets and design strategies for anti-cancer drugs.
• It evaluates the advantages and disadvantages of current anti-cancer methods and targets used in clinical studies.
• The findings provide insights into optimizing anti-cancer drug development and clinical application.